Cleavage of TANK-Binding Kinase 1 by HIV-1 Protease Triggers Viral Innate Immune Evasion.
HIV-1 protease
TANK binding kinase-1
immune evasion
pathogenic fitness
type-I interferon
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
12
2020
accepted:
01
04
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Type-I interferons (IFN-I) are the innate immune system's principal defense against viral infections. Human immunodeficiency virus-1 (HIV-1) has evolved several ways to suppress or evade the host's innate immunity in order to survive and replicate to sustain infection. Suppression of IFN-I is one among the multiple escape strategies used by HIV-1 to prevent its clearance. HIV-1 protease which helps in viral maturation has also been observed to cleave host cellular protein kinases. In this study we performed a comprehensive screening of a human kinase library using AlphaScreen assay and identified that TANK binding kinase-1 (TBK1) was cleaved by HIV-1 protease (PR). We demonstrate that PR cleaved TBK1 fails to phosphorylate IFN regulatory factor 3 (IRF3), thereby reducing the IFN-I promoter activity and further reveal that the PR mediated suppression of IFN-I could be counteracted by protease inhibitors (PI)
Identifiants
pubmed: 33986734
doi: 10.3389/fmicb.2021.643407
pmc: PMC8110901
doi:
Types de publication
Journal Article
Langues
eng
Pagination
643407Informations de copyright
Copyright © 2021 Jeremiah, Miyakawa, Matsunaga, Nishi, Kudoh, Takaoka, Sawasaki and Ryo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Retrovirology. 2016 Sep 09;13(1):66
pubmed: 27613235
Biochemistry. 2013 May 14;52(19):3278-88
pubmed: 23566104
Cytokine. 2008 Sep;43(3):336-41
pubmed: 18694646
J Proteome Res. 2010 Aug 6;9(8):4264-73
pubmed: 20575507
Curr Opin Microbiol. 2016 Aug;32:113-119
pubmed: 27288760
Virology. 2008 Mar 30;373(1):85-97
pubmed: 18082865
Immunity. 2011 Mar 25;34(3):340-51
pubmed: 21419663
J Virol. 2012 Aug;86(16):8367-74
pubmed: 22593165
Antiviral Res. 2005 Apr;66(1):47-55
pubmed: 15781132
Virology. 2015 May;479-480:403-17
pubmed: 25816761
J Immunol. 2010 Jul 1;185(1):424-32
pubmed: 20511549
iScience. 2020 Mar 27;23(3):100867
pubmed: 32105634
Front Immunol. 2018 Jan 15;8:1823
pubmed: 29379496
Virology. 2005 Jan 5;331(1):181-9
pubmed: 15582665
J Virol. 2011 Aug;85(16):7965-75
pubmed: 21653671
Retrovirology. 2015 Aug 22;12:74
pubmed: 26297639
Front Immunol. 2020 Mar 24;11:534
pubmed: 32265942
PLoS Pathog. 2018 Aug 16;14(8):e1007148
pubmed: 30114241
Nat Microbiol. 2019 Jun;4(6):1006-1013
pubmed: 30833734
Mob DNA. 2019 Aug 22;10:36
pubmed: 31462935
FEBS Lett. 2002 Mar 6;514(1):102-5
pubmed: 11904190
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E590-E599
pubmed: 28069935
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9571-6
pubmed: 8790371
Sci Rep. 2015 Nov 13;5:16445
pubmed: 26563568
Front Immunol. 2018 Sep 11;9:2061
pubmed: 30254639
Front Immunol. 2019 Jul 24;10:1736
pubmed: 31396233
Nat Immunol. 2015 Jun;16(6):554-62
pubmed: 25988887
J Virol. 2019 Oct 15;93(21):
pubmed: 31413127
Antimicrob Agents Chemother. 2010 Oct;54(10):4253-61
pubmed: 20660676
Retrovirology. 2014 Jan 22;11:9
pubmed: 24447338
Cells. 2020 Jan 20;9(1):
pubmed: 31968566
Nature. 2019 Jan;565(7740):500-504
pubmed: 30626973
Cell Biosci. 2012 Sep 12;2(1):32
pubmed: 22971934
Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10707-E10716
pubmed: 29180435
Front Immunol. 2018 Jan 30;9:84
pubmed: 29441066
Front Immunol. 2018 Dec 06;9:2876
pubmed: 30574147
J Gen Virol. 2006 Jul;87(Pt 7):2041-2046
pubmed: 16760407
J Virol. 2015 Jul;89(13):6575-84
pubmed: 25855743